NBIX
Neurocrine Biosciences Inc.
$146.62
+$1.39(+0.96%)
67
Overall
60
Value
75
Tech
--
Quality
Market Cap
$13.97B
Volume
700.62K
52W Range
$84.23 - $154.61
Target Price
$166.44
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $39.5M | $15.0M | $161.6M | $451.2M | $788.1M | $1.0B | $1.1B | $1.5B | $1.9B | $2.4B | ||
| Total Revenue | $19.8M | $15.0M | $161.6M | $451.2M | $788.1M | $1.0B | $1.1B | $1.5B | $1.9B | $2.4B | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | -- | -- | $1.3M | $4.9M | -- | $10.1M | $14.3M | $23.2M | $39.7M | $34.0M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $19.8M | $15.0M | $160.4M | $451.2M | $788.1M | $1.0B | $1.1B | $1.5B | $1.8B | $2.3B | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $114.0M | $162.4M | $293.0M | $414.3M | $715.8M | $882.9M | $1.0B | $1.2B | $1.6B | $1.8B | ||
| Research & Development | $81.5M | $94.3M | $121.8M | $4.8M | $154.3M | $164.5M | $433.4M | $463.8M | $708.9M | $743.6M | ||
| Research Expense | $81.5M | $94.3M | $121.8M | $160.5M | -- | -- | $328.1M | $463.8M | $565.0M | $731.1M | ||
| Selling, General & Administrative | $32.5M | $68.1M | $169.9M | $248.9M | $354.1M | $433.3M | $583.3M | $752.7M | $887.6M | $1.0B | ||
| Selling & Marketing Expenses | -- | -- | -- | -- | $40.6M | $64.8M | $139.8M | $149.7M | $159.9M | $191.0M | ||
| General & Administrative Expenses | $32.5M | $68.1M | $169.9M | $248.9M | $354.1M | $433.3M | $583.3M | $752.7M | $887.6M | $1.0B | ||
| Promotion & Advertising | -- | -- | -- | -- | $40.6M | $64.8M | $139.8M | -- | -- | -- | ||
| Depreciation & Amortization | $1.0M | $1.5M | $2.4M | $4.0M | $7.4M | $8.6M | $10.9M | $15.1M | $17.8M | $23.5M | ||
| Depreciation & Amortization | $1.0M | $1.5M | $2.4M | $4.0M | $7.4M | $8.6M | $10.9M | -- | -- | -- | ||
| Amortization | -- | -- | -- | -- | -- | -- | $17.3M | $38.4M | $35.5M | $163.1M | ||
| Other Operating Expenses | $-2.6M | $-2.2M | $-3.3M | $-160.7M | $-207.4M | $-285.1M | $-4.9M | -- | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-94.2M | $-147.4M | $-131.4M | $36.9M | $72.3M | $163.0M | $102.5M | $249.0M | $250.9M | $570.5M | ||
| EBITDA | $-62.1M | $-136.1M | $-107.1M | $76.7M | $106.2M | $148.1M | $138.1M | $237.8M | $353.4M | $513.1M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | -- | $19.5M | $30.5M | $32.0M | $32.8M | $25.8M | $7.1M | $4.6M | -- | ||
| Intinc | $1.9M | $2.8M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $1.9M | $2.8M | $-19.5M | $-30.5M | $-32.0M | $-32.8M | $-25.8M | $-7.1M | $-4.6M | -- | ||
| Gain on Sale of Securities | $1.9M | $2.8M | $6.2M | -- | -- | -- | -- | -- | -- | $-9.6M | ||
| Other Income/Expense | $-5.3M | $-6.3M | $-8.3M | $-15.5M | $-6.2M | $23.5M | $-24.7M | $-28.0M | $-28.4M | $37.1M | ||
| Other Special Charges | $3.3M | $3.4M | $8.3M | $15.5M | $19.2M | $-5.8M | $3.8M | $-70.0M | -- | $-2.2M | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-69.2M | $-141.1M | $-123.0M | $52.4M | $78.5M | $139.5M | $127.2M | $221.0M | $332.1M | $486.0M | ||
| Pre-Tax Income | $-69.2M | $-141.1M | $-142.5M | $21.8M | $46.5M | $106.7M | $101.4M | $213.9M | $332.1M | $486.0M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | -- | -- | $-4.0M | $730.0K | $9.5M | $-300.6M | $11.8M | $59.4M | $82.4M | $144.7M | ||
| NET INCOME | ||||||||||||
| Net Income | $-88.9M | $-141.1M | $-142.5M | $21.1M | $37.0M | $407.3M | $89.6M | $154.5M | $249.7M | $341.3M | ||
| Net Income (Continuing Operations) | $-88.9M | $-141.1M | $-142.5M | $21.1M | $37.0M | $407.3M | $89.6M | $154.5M | $249.7M | $341.3M | ||
| Net Income (Discontinued Operations) | $-88.9M | $-141.1M | $-142.5M | $21.1M | $37.0M | $407.3M | $89.6M | $154.5M | $249.7M | $341.3M | ||
| Net Income (Common Stockholders) | $-69.2M | $-141.1M | $-142.5M | $342.4M | $451.8M | $407.3M | $89.6M | $154.5M | $249.7M | $341.3M | ||
| Normalized Income | $-45.0M | $-91.7M | $-146.6M | $17.3M | $36.7M | $-193.9M | -- | -- | -- | $481.1M | ||
| TOTALS | ||||||||||||
| Total Expenses | $114.0M | $162.4M | $294.2M | $414.3M | $715.8M | $882.9M | $1.0B | $1.2B | $1.6B | $1.8B | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $84.5M | $86.7M | $88.1M | $90.2M | $91.6M | $93.1M | $94.6M | $95.8M | $97.7M | $100.4M | ||
| Average Shares Outstanding (Diluted) | $84.5M | $86.7M | $88.1M | $95.4M | $95.7M | $97.8M | $97.9M | $98.9M | $101.0M | $103.7M | ||
| Shares Outstanding | $86.5M | $87.1M | $89.3M | $90.8M | $92.3M | $93.9M | $95.2M | $96.6M | $99.5M | $99.7M | ||
| Basic EPS | $-1.05 | $-1.63 | $-1.62 | $0.23 | $0.40 | $4.38 | $0.95 | $1.61 | $2.56 | $3.4 | ||
| Basic EPS (Continuing Operations) | $-1.05 | $-1.63 | $-1.62 | $0.23 | $0.40 | $4.38 | $0.95 | $1.61 | $2.56 | $3.4 | ||
| Diluted EPS | $-1.05 | $-1.63 | $-1.62 | $0.22 | $0.39 | $4.16 | $0.92 | $1.56 | $2.47 | $3.29 | ||
| Diluted EPS (Continuing Operations) | $-1.05 | $-1.63 | $-1.62 | $0.22 | $0.39 | $4.16 | $0.92 | $1.56 | $2.47 | $3.29 | ||
| OTHER METRICS | ||||||||||||
| Development Expense | -- | -- | -- | $4.8M | $154.3M | $164.5M | $105.3M | -- | $143.9M | $12.5M | ||
| Other Gand A | $32.5M | $68.1M | $169.9M | $248.9M | $354.1M | $433.3M | $583.3M | $752.7M | $887.6M | $1.0B | ||
| Rent And Landing Fees | $6.0M | $6.0M | $5.9M | $6.9M | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NBIX | $146.62 | +1.0% | 700.62K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Neurocrine Biosciences Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW